2025.02.28本文字数:3467,阅读时长大约9分钟导读:2月27日晚间,圣湘生物披露2024年度业绩快报,公司营收达14.97亿元,同比增长48.60%,其中呼吸道类产品收入翻倍成为增长引擎。与此同时,圣湘生物在并购领域动作频频,继年初收购中山海济后,又于2月26日宣布收购红岸基元54%股权。然而,随着新冠红利退潮,公司净利润下滑28.78%,其并购战略也面临市场检验。2月27日晚间,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.